Carmel Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Carmel Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-25,594	Closed	-$2.3M	–	26
2024 Q4	$2.3M	Sell	25,594 -10,275	-29%	-$995K	0.87%	23
2024 Q3	$3.54M	Sell	35,869 -375	-1%	-$36.8K	1.33%	23
2024 Q2	$3.36M	Sell	36,244 -4,515	-11%	-$405K	1.31%	23
2024 Q1	$3.87M	Buy	40,759 +18,283	+81%	+$1.7M	1.59%	23
2023 Q4	$2.01M	Sell	22,476 -600	-3%	-$44.6K	0.96%	23
2023 Q3	$1.69M	Sell	23,076 -470	-2%	-$37.5K	0.95%	23
2023 Q2	$1.96M	Buy	23,546 +675	+3%	+$56.4K	1.02%	25
2023 Q1	$1.74M	Buy	22,871 +1,550	+7%	+$129K	1%	27
2022 Q4	$1.77M	Buy	21,321 +2,625	+14%	+$213K	1.09%	27
2022 Q3	$1.48M	Buy	18,696 +725	+4%	+$61.1K	0.97%	29
2022 Q2	$1.33M	Sell	17,971 -9,715	-35%	-$729K	0.83%	29
2022 Q1	$2.49M	Buy	27,686 +950	+4%	+$87.7K	1.3%	26
2021 Q4	$2.99M	Buy	+26,736	New	+$3.22M	1.47%	23

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Carmel Capital Management's XBI Position: Q1 2025 in Review

Carmel Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 25,594 shares — an estimated $2.3M sold.

Carmel Capital Management first reported a position in XBI in Q4 2021 and held it in 13 quarters. The position peaked at $3.87M in Q1 2024. 682 funds tracked by Wall St. Rank hold XBI as of Q1 2025.

Carmel Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
Carmel Capital Management sold 25,594 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $2.3M.
Carmel Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 13 quarters.
Carmel Capital Management's State Street SPDR S&P Biotech ETF position peaked at $3.87M in Q1 2024.
682 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.

Based on Carmel Capital Management's 13F filing for Q1 2025, filed 29 Apr 2025.